Related Experiment Video
Updated: Jul 29, 2025

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish
Published on: June 7, 2018
Cardiovascular Safety of Hydroxychloroquine-Azithromycin in 424 COVID-19 Patients
Matthieu Million1,2, Jean-Christophe Lagier1,2, Jérôme Hourdain3,4
1IHU-Méditerranée Infection, 13005 Marseille, France.
Insights
Hydroxychloroquine and azithromycin treatment for COVID-19 can be safely administered with careful patient screening. A simple safety approach involving ECG and electrolyte assessment identified contraindications, ensuring no major cardiac events in treated patients.
Area of Science:
- Cardiology
- Infectious Diseases
- Pharmacology
Background:
- Hydroxychloroquine (HCQ) and azithromycin (AZM) combination was widely used for COVID-19 despite concerns about cardiac repolarization prolongation.
- Potential for QT interval prolongation necessitates careful safety evaluations for this drug combination.
Purpose of the Study:
- To report a pragmatic safety approach for administering HCQ-AZ to COVID-19 patients.
- To assess the safety and identify contraindications for HCQ-AZ treatment in a real-world setting.
Main Methods:
- Implementation of a safety protocol including baseline ECG, corrected QT interval (QTc) assessment, and electrolyte evaluation.
- Exclusion criteria included severe heart disease, QTc > 500 ms, hypokalemia, or interacting medications.
- ECG and QTc were monitored at admission and after 48 hours of treatment.
Main Results:
- Out of 424 patients, 11 (2.6%) had contraindications; 413 were treated without arrhythmic events during 10-day regimen.
- A statistically significant, slight QTc prolongation of 3.75 ± 25.4 ms was observed after 2 days (p = 0.003).
- Ten patients (2.4%) experienced QTc prolongation > 60 ms, but none exceeded 500 ms.
Conclusions:
- A simple initial assessment of medical history, ECG, and kalemia effectively identifies patients contraindicated for HCQ-AZ.
- This approach enables the safe treatment of COVID-19 patients with HCQ-AZ, minimizing cardiac risks.
- Strict protocols and interdisciplinary collaboration allow safe use of QT-prolonging drugs in life-threatening infections.
Abstract:
Background and Objectives: Hydroxychloroquine (HCQ) combined with azithromycin (AZM) has been widely administered to patients with COVID-19 despite scientific controversies. In particular, the potential of prolong cardiac repolarization when using this combination has been discussed. Materials and Methods: We report a pragmatic and simple safety approach which we implemented among the first patients treated for COVID-19 in our center in early 2020. Treatment contraindications were the presence of severe structural or electrical heart disease, baseline corrected QT interval (QTc) > 500 ms, hypokalemia, or other drugs prolonging QTc that could not be interrupted. Electrocardiogram and QTc was evaluated at admission and re-evaluated after 48 h of the initial prescription. Results: Among the 424 consecutive adult patients (mean age 46.3 ± 16.1 years; 216 women), 21.5% patients were followed in conventional wards and 78.5% in a day-care unit. A total of 11 patients (2.6%) had contraindications to the HCQ-AZ combination. In the remaining 413 treated patients, there were no arrhythmic events in any patient during the 10-day treatment regimen. QTc was slightly but statistically significantly prolonged by 3.75 ± 25.4 ms after 2 days of treatment (p = 0.003). QTc prolongation was particularly observed in female outpatients <65 years old without cardiovascular disease. Ten patients (2.4%) developed QTc prolongation > 60 ms, and none had QTc > 500 ms. Conclusions: This report does not aim to contribute to knowledge of the efficacy of treating COVID-19 with HCQ-AZ. However, it shows that a simple initial assessment of patient medical history, electrocardiogram (ECG), and kalemia identifies contraindicated patients and enables the safe treatment of COVID-19 patients with HCQ-AZ. QT-prolonging anti-infective drugs can be used safely in acute life-threatening infections, provided that a strict protocol and close collaboration between infectious disease specialists and rhythmologists are applied.
Related Concept Videos
Myocarditis III: Medical Management
Rheumatic Heart Disease III: Medical Management
Antihypertensive Drugs: Thiazide-Class Diuretics
Heart Failure V: Medical Management
Rheumatic Heart Disease IV: Nursing Management
Pericarditis III: Medical Management

